Jian Luo1, Trevor Duke2, Mohammod Jobayer Chisti3, Elizabeth Kepreotes4, Valerie Kalinowski5, Jie Li6. 1. Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu, China. 2. Center for International Child Health, The University of Melbourne Department of Pediatrics, Murdoch Children's Research Institute and Intensive Care Unit, Royal Children's Hospital, Melbourne, Victoria, Australia. 3. Center for International Child Health, The University of Melbourne Department of Pediatrics, Murdoch Children's Research Institute and Intensive Care Unit, Royal Children's Hospital, Melbourne, Victoria, Australia; Intensive Care Unit, Dhaka Hospital, Nutrition and Clinical Services Division, International Center for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh. 4. John Hunter Children's Hospital, Hunter Medical Research Institute, University of Newcastle GrowUpWell, Priority Research Center, Australia. 5. Pediatric ICU, Rush University Children's Hospital, Chicago, IL. 6. Division of Respiratory Care, Department of Cardiopulmonary Sciences, Rush University Medical Center, Rush University, Chicago, IL. Electronic address: Jie_Li@rush.edu.
Abstract
OBJECTIVES: To evaluate the efficacy of high-flow nasal cannula (HFNC) oxygen therapy in providing respiratory support of children with acute lower respiratory infection (ALRI), hypoxemia, and respiratory distress. STUDY DESIGN: We performed a meta-analysis of randomized controlled trials that compared HFNC and standard flow oxygen therapy or nasal continuous positive airway pressure (nCPAP) and reported treatment failure as an outcome. Data were synthesized using Mann-Whitney U test. RESULTS: Compared with standard oxygen therapy, HFNC significantly reduced treatment failure (risk ratio [RR] 0.49, 95% CI 0.40-0.60, P < .001) in children with mild hypoxemia (arterial pulse oximetry [SpO2] >90% on room air). HFNC had an increased risk of treatment failure compared with nCPAP in infants age 1-6 months with severe hypoxemia (SpO2 <90% on room air or SpO2 >90% on supplemental oxygen) (RR 1.77, 95% CI 1.17-2.67, P = .007). No significant differences were found in intubation rates and mortality between HFNC and standard oxygen therapy or nCPAP. HFNC had a lower risk of nasal trauma compared with nCPAP (RR 0.35, 95% CI 0.16-0.77, P = .009). CONCLUSIONS: Among children <5 years of age with ALRI, respiratory distress, and mild hypoxemia, HFNC reduced the risk of treatment failure when compared with standard oxygen therapy. However, nCPAP was associated with a lower risk of treatment failure than HFNC in infants age 1-6 months with ALRI, moderate-to-severe respiratory distress, and severe hypoxemia. No differences were found in intubation and mortality between HFNC and standard oxygen therapy or nCPAP.
OBJECTIVES: To evaluate the efficacy of high-flow nasal cannula (HFNC) oxygen therapy in providing respiratory support of children with acute lower respiratory infection (ALRI), hypoxemia, and respiratory distress. STUDY DESIGN: We performed a meta-analysis of randomized controlled trials that compared HFNC and standard flow oxygen therapy or nasal continuous positive airway pressure (nCPAP) and reported treatment failure as an outcome. Data were synthesized using Mann-Whitney U test. RESULTS: Compared with standard oxygen therapy, HFNC significantly reduced treatment failure (risk ratio [RR] 0.49, 95% CI 0.40-0.60, P < .001) in children with mild hypoxemia (arterial pulse oximetry [SpO2] >90% on room air). HFNC had an increased risk of treatment failure compared with nCPAP in infants age 1-6 months with severe hypoxemia (SpO2 <90% on room air or SpO2 >90% on supplemental oxygen) (RR 1.77, 95% CI 1.17-2.67, P = .007). No significant differences were found in intubation rates and mortality between HFNC and standard oxygen therapy or nCPAP. HFNC had a lower risk of nasal trauma compared with nCPAP (RR 0.35, 95% CI 0.16-0.77, P = .009). CONCLUSIONS: Among children <5 years of age with ALRI, respiratory distress, and mild hypoxemia, HFNC reduced the risk of treatment failure when compared with standard oxygen therapy. However, nCPAP was associated with a lower risk of treatment failure than HFNC in infants age 1-6 months with ALRI, moderate-to-severe respiratory distress, and severe hypoxemia. No differences were found in intubation and mortality between HFNC and standard oxygen therapy or nCPAP.
Authors: Padmanabhan Ramnarayan; Alvin Richards-Belle; Laura Drikite; Michelle Saull; Izabella Orzechowska; Robert Darnell; Zia Sadique; Julie Lester; Kevin P Morris; Lyvonne N Tume; Peter J Davis; Mark J Peters; Richard G Feltbower; Richard Grieve; Karen Thomas; Paul R Mouncey; David A Harrison; Kathryn M Rowan Journal: JAMA Date: 2022-07-12 Impact factor: 157.335
Authors: Holger J Schünemann; Joanne Khabsa; Karla Solo; Assem M Khamis; Romina Brignardello-Petersen; Amena El-Harakeh; Andrea Darzi; Anisa Hajizadeh; Antonio Bognanni; Anna Bak; Ariel Izcovich; Carlos A Cuello-Garcia; Chen Chen; Ewa Borowiack; Fatimah Chamseddine; Finn Schünemann; Gian Paolo Morgano; Giovanna E U Muti-Schünemann; Guang Chen; Hong Zhao; Ignacio Neumann; Jan Brozek; Joel Schmidt; Layal Hneiny; Leila Harrison; Marge Reinap; Mats Junek; Nancy Santesso; Rayane El-Khoury; Rebecca Thomas; Robby Nieuwlaat; Rosa Stalteri; Sally Yaacoub; Tamara Lotfi; Tejan Baldeh; Thomas Piggott; Yuan Zhang; Zahra Saad; Bram Rochwerg; Dan Perri; Eddy Fan; Florian Stehling; Imad Bou Akl; Mark Loeb; Paul Garner; Stephen Aston; Waleed Alhazzani; Wojciech Szczeklik; Derek K Chu; Elie A Akl Journal: Ann Intern Med Date: 2020-05-22 Impact factor: 25.391
Authors: Anna Christina Meyer; Jens Spiesshoefer; Nina Christina Siebers; Anna Heidbreder; Christian Thiedemann; Hartmut Schneider; Andrew T Braun; Winfried Randerath; Peter Young; Michael Dreher; Matthias Boentert Journal: Sleep Breath Date: 2020-12-02 Impact factor: 2.816
Authors: Ali Alsuheel Asseri; Youssef Ali AlQahtani; Ahmad Ali Alhanshani; Ghada Haider Ali; Ibrahim Alhelali Journal: Pediatric Health Med Ther Date: 2021-08-31
Authors: A Rosala-Hallas; Ashley P Jones; Paula R Williamson; Emma Bedson; Vanessa Compton; Ricardo M Fernandes; David Lacy; Mark David Lyttle; Matthew Peak; Kentigern Thorburn; Kerry Woolfall; Clare Van Miert; Paul S McNamara Journal: BMJ Open Date: 2022-03-09 Impact factor: 2.692
Authors: Kristen L Sessions; Andrew G Smith; Peter J Holmberg; Brian Wahl; Tisungane Mvalo; Mohammod J Chisti; Ryan W Carroll; Eric D McCollum Journal: Arch Dis Child Date: 2021-12-08 Impact factor: 4.920